Sarah M Wade1, Trudy McGarry1, Siobhan C Wade2, Ursula Fearon1, Douglas J Veale3. 1. S.M. Wade, PhD, T. McGarry, PhD, U. Fearon, PhD, Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, and Centre for Arthritis and Rheumatic Disease, St. Vincent's University Hospital, and University College Dublin. 2. S.C. Wade, PhD, Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin. 3. D.J. Veale, MD, Centre for Arthritis and Rheumatic Disease, St. Vincent's University Hospital, and University College Dublin, Dublin, Ireland. douglas.veale@ucd.ie.
Abstract
OBJECTIVE: MicroRNA (miRNA) are small endogenous regulatory RNA molecules that have emerged as potential therapeutic targets and biomarkers in autoimmunity. Here, we investigated serum miRNA levels in patients with psoriatic arthritis (PsA) and further assessed a serum miRNA signature in therapeutic responder versus nonresponder PsA patients. METHODS: Serum samples were collected from healthy controls (HC; n = 20) and PsA patients (n = 31), and clinical demographics were obtained. To examine circulatory miRNA in serum from HC and PsA patients, a focused immunology miRNA panel was analyzed utilizing a miRNA Fireplex assay (FirePlex Bioworks Inc.). MiRNA expression was further assessed in responders versus nonresponders according to the European League Against Rheumatism response criteria. RESULTS: Six miRNA (miR-221-3p, miR-130a-3p, miR-146a-5p, miR-151-5p, miR-26a-5p, and miR-21-5p) were significantly higher in PsA compared to HC (all P < 0.05), with high specificity and sensitivity determined by receiver-operating characteristic curve analysis. Analysis of responder versus nonresponders demonstrated higher baseline levels of miR-221-3p, miR-130a-3p, miR-146a-5p, miR-151-5p, and miR-26a-5p were associated with therapeutic response. CONCLUSION: This study identified a 6-serum microRNA signature that could be attractive candidates as noninvasive markers for PsA and may help to elucidate the disease pathogenesis.
OBJECTIVE: MicroRNA (miRNA) are small endogenous regulatory RNA molecules that have emerged as potential therapeutic targets and biomarkers in autoimmunity. Here, we investigated serum miRNA levels in patients with psoriatic arthritis (PsA) and further assessed a serum miRNA signature in therapeutic responder versus nonresponder PsApatients. METHODS: Serum samples were collected from healthy controls (HC; n = 20) and PsApatients (n = 31), and clinical demographics were obtained. To examine circulatory miRNA in serum from HC and PsApatients, a focused immunology miRNA panel was analyzed utilizing a miRNA Fireplex assay (FirePlex Bioworks Inc.). MiRNA expression was further assessed in responders versus nonresponders according to the European League Against Rheumatism response criteria. RESULTS: Six miRNA (miR-221-3p, miR-130a-3p, miR-146a-5p, miR-151-5p, miR-26a-5p, and miR-21-5p) were significantly higher in PsA compared to HC (all P < 0.05), with high specificity and sensitivity determined by receiver-operating characteristic curve analysis. Analysis of responder versus nonresponders demonstrated higher baseline levels of miR-221-3p, miR-130a-3p, miR-146a-5p, miR-151-5p, and miR-26a-5p were associated with therapeutic response. CONCLUSION: This study identified a 6-serum microRNA signature that could be attractive candidates as noninvasive markers for PsA and may help to elucidate the disease pathogenesis.
Authors: Anna Scanu; Mariagrazia Lorenzin; Roberto Luisetto; Paola Galozzi; Augusta Ortolan; Francesca Oliviero; Andrea Doria; Roberta Ramonda Journal: Exp Biol Med (Maywood) Date: 2022-04-26
Authors: Clare C Cunningham; Sarah Wade; Achilleas Floudas; Carl Orr; Trudy McGarry; Siobhan Wade; Sian Cregan; Ursula Fearon; Douglas J Veale Journal: Front Immunol Date: 2021-03-03 Impact factor: 7.561
Authors: Francesca Motta; Andrea Pederzani; Maria Cristina Carena; Angela Ceribelli; Paul B Wordsworth; Maria De Santis; Carlo Selmi; Matteo Vecellio Journal: Curr Rheumatol Rep Date: 2021-07-03 Impact factor: 4.592